Study finds HER2 breast cancer driver in 3 percent of lung cancers
A study by the University of Colorado Cancer Center found approximately 3 percent of lung cancer patients are found to have the HER2 breast cancer driver gene. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 27, 2017 Category: Consumer Health News Source Type: news

FDA Panel Backs Trastuzumab Biosimilar
The FDA Oncologic Drugs Advisory Committee has unanimously voted to recommend approval of the trastuzumab biosimilar MYL-1401O for the treatment of HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 27, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Study finds breast cancer driver, HER2, in 3 percent of lung cancers
(University of Colorado Anschutz Medical Campus) The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced-stage lung cancer had mutations in the gene HER2. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 27, 2017 Category: Cancer & Oncology Source Type: news

NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting
CARY, N.C. (July 21, 2017) — Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected to be in the limited distribution network for Puma Biotechnology, Inc.’s new product, NERLYNX, a kinase inhibitor approved by the U.S. Food and Drug Admi... (Source: McKesson News)
Source: McKesson News - July 21, 2017 Category: Information Technology Source Type: news

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
This research article has led to a Practice Changing Update on DynaMed Plus. It concludes that capecitabine adjuvant therapy may improve survival in women with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 19, 2017 Category: Consumer Health News Source Type: news

FDA Approves Neratinib for HER2-Positive Breast Cancer
The FDA has approved neratinib (Nerlynx) for use as extended adjuvant treatment in adult patients with early-stage HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 19, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

FDA Approves Nerlynx to Help Prevent HER2 + Breast CA Return
Drug is a kinase inhibitor that works by blocking several enzymes that promote cell growth (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 19, 2017 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Institutional, Source Type: news

FDA approves Nerlynx to reduce risk of recurrent breast cancer
The U.S. Food and Drug Administration today approved the use of Nerlynx to treat early-stage HER2-positive breast cancer to lower remission risk. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 18, 2017 Category: Consumer Health News Source Type: news

Nerlynx Approved to Help Prevent Breast Cancer's Return
TUESDAY, July 18, 2017 -- Nerlynx (neratinib) has been approved by the U.S. Food and Drug Administration to help prevent HER2-positive breast cancer from returning. It's the first drug designed to prevent return of HER2-positive breast cancer, a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 18, 2017 Category: General Medicine Source Type: news

FDA OKs First'Extended' Adjuvant Treatment for HER2 Breast Cancer FDA OKs First'Extended' Adjuvant Treatment for HER2 Breast Cancer
The FDA has approved a new drug for patients with early-stage HER2-positive breast cancer who have completed trastuzumab and want"extended" adjuvant therapy.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Neratinib Approved for Extended Adjuvant Breast Ca Treatment
(MedPage Today) -- Drug targets epidermal growth factor receptors HER2 and EGFR (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 17, 2017 Category: American Health Source Type: news

FDA Approves Nerlynx (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
July 17, 2017 -- The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type of cancer, Nerlynx is the first extended adjuvant... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 17, 2017 Category: Drugs & Pharmacology Source Type: news

FDA approves new treatment to reduce the risk of breast cancer returning
The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer. For patients with this type of cancer, Nerlynx is the first extended adjuvant therapy, a form of therapy that is taken after an initial treatment to further lower the risk of the cancer coming back. Nerlynx is indicated for adult patients who have been previously treated with a regimen that includes the drug trastuzumab. (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 17, 2017 Category: American Health Source Type: news

T-DM1 Promising as Neoadjuvant Therapy in Early BC (CME/CE)
(MedPage Today) -- 41% of HER2+/HR+ patients achieved a pathologic complete response (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 16, 2017 Category: Hematology Source Type: news

T-DM1 in Early HER2+/HR+ Breast Cancer Offers Good Response Rates
T-DM1 administered for 12 weeks with or without endocrine therapy yields good rates of pathologic complete response in women with HER2-positive/hormone receptor –positive breast cancer, according to a new randomized trial. (Source: CancerNetwork)
Source: CancerNetwork - July 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Oncologists See Promise in Neratinib, New Oral HER2-Positive Drug Oncologists See Promise in Neratinib, New Oral HER2-Positive Drug
Half of those asked in a Medscape survey rated neratinib, which is pending approval by the FDA later this month, as an important or very important alternative in treating HER2-positive breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

ASCO Panel Backs Gene Assay for Breast Cancer
(MedPage Today) -- MammaPrint OK'd for clinically high-risk HR-positive, HER2-negative disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 11, 2017 Category: Hematology Source Type: news

Puma closes patient enrolment in Phase III breast cancer trial of neratinib
Puma Biotechnology has completed patient enrolment in the Phase III NALA trial of its lead drug candidate PB272 (neratinib) for the treatment of HER2-positive metastatic breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - July 10, 2017 Category: Pharmaceuticals Source Type: news

Potential ASCO Practice-Changers in HER2+ Breast Cancer Potential ASCO Practice-Changers in HER2+ Breast Cancer
Oncologists will debate the APHINITY trial data for years to come, says Dr Kevin Kalinsky.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 7, 2017 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Are Biobetters Better?
Biosimilars and biobetters are both variants of a biologic drug, however, while biosimilars are close copies of the originator, biobetters have been improved, for example, in terms of efficacy, safety, tolerability or dosing regimen.Regulators consider biobetters as new products and so afford them the same patent protection as any originator, however, this means they require the same clinical and non-clinical data packages. Conversely, a reduced clinical data package is an attractive element for the development of biosimilars.Given the cost of development and the time pressure to bring a biobetter to market before biosimil...
Source: EyeForPharma - July 3, 2017 Category: Pharmaceuticals Authors: James Wright Source Type: news

Abemaciclib Shows Activity for HR-Positive Breast Cancer Brain Mets
This video examines an early trial studying abemaciclib for the treatment of brain metastases in patients with hormone receptor –positive, HER2-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 30, 2017 Category: Cancer & Oncology Authors: Sara M. Tolaney, MD, MPH Tags: News Videos Breast Cancer Source Type: news

Long-Term Data Confirm TH Benefit in Early HER2-Positive Breast Cancer
This video highlights 7-year follow-up data from the APT trial, which studied adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 30, 2017 Category: Cancer & Oncology Authors: Sara M. Tolaney, MD, MPH Tags: News Videos Breast Cancer Source Type: news

Novel Therapies in Development for HER2-Amplified Breast Cancer
In this interview we discuss some of the novel therapeutics in development for HER2-amplified breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 27, 2017 Category: Cancer & Oncology Authors: Sherene Loi, MD, PhD Tags: Breast Cancer HER2-Positive Breast Cancer Q & Source Type: news

Biosimilar for HER2-Positive Breast Cancer Equivalent to Trastuzumab
A biosimilar to trastuzumab known as CT-P6 showed equivalent efficacy and similar toxicity to the original agent in patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 26, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news

EMA Panel Likes Breast and Kidney Cancer Drugs EMA Panel Likes Breast and Kidney Cancer Drugs
The Committee for Medicinal Products for Human Use recommended approval of ribociclib for advanced HER+/HER2- breast cancer and tivozanib for advanced renal cell carcinoma.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Imagion Biosystems raises $9m with Aussie IPO
Imagion Biosystems (ASX:IBX) said today that it raised $9.1 million (A$12 million) in an initial public offering on the Australian stock exchange for its MagSense cancer-tagging nanoparticles. The 15.1¢-per-share (A20¢) flotation of 60 million shares is earmarked for 1st-in-human trials, expected during the 2nd half of 2018, the Albuquerque-based company said. The MagSense nanoparticles have a 25nm iron oxide core and a specialized polymer coating and are designed to work with tumor-targeting biomarkers to attach themselves to cancer cells. Because they behave differently when bound to a cell antibody than w...
Source: Mass Device - June 22, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Diagnostics Funding Roundup Initial Public Offering (IPO) Oncology Wall Street Beat imagionbiosystems Source Type: news

Adjuvant Capecitabine Improves Survival in Residual Invasive Breast Cancer
Patients with HER2-negative breast cancer with residual invasive disease following neoadjuvant chemotherapy benefit from adjuvant treatment with capecitabine. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer News Source Type: news

ASCO 2017: Updates on HER2-Positive Breast Cancer Treatment
This video highlights the latest studies presented at the 2017 ASCO Annual Meeting on the treatment of HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 13, 2017 Category: Cancer & Oncology Authors: Karen Gelmon, MD Tags: Conferences/ASCO Street Team News Videos Breast Cancer Source Type: news

Another CDK4/6 Inhibitor Boosts PFS in Breast Cancer
(MedPage Today) -- Abemaciclib-fulvestrant combo for advanced HR+/HER2- disease (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 8, 2017 Category: Primary Care Source Type: news

Dual HER2 Blockade Superior to Single Blockade for HER2+/HR+ Breast Cancer
Dual HER2 blockade was superior to single blockade in postmenopausal women with HER2-positive, HR-positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 8, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Breast Cancer News Source Type: news

Two Anti-HER2 Drugs Slightly Better Than One
(MedPage Today) -- Patient selection key to addition of pertuzumab to trastuzumab (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 7, 2017 Category: Hematology Source Type: news

Pertuzumab Combo Improved Invasive DFS in HER2-Positive Breast Cancer
The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease –free survival in patients with HER2-positive early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer News Source Type: news

Oral SERD Promising in ER-Positive Breast Cancer With ESR1 Mutations
The investigational third-generation nonsteroidal oral selective estrogen receptor degrader RAD1901 was associated with a 23% objective response rate among 40 heavily pretreated women with estrogen receptor (ER)-positive, HER2-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Conferences/ASCO Breast Cancer News Source Type: news

Neratinib Shrunk Brain Mets in Half of HER2+ Breast Cancer Patients
This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Rachel A. Freedman, MD, MPH Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer Videos Breast Cancer Source Type: news

Neratinib Shrank Brain Mets in Half of HER2+ Breast Cancer Patients
This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Rachel A. Freedman, MD, MPH Tags: Conferences/ASCO Breast Cancer HER2-Positive Breast Cancer News Videos Breast Cancer Source Type: news

First Look at New CDK 4/6 Data in Metastatic Breast Cancer First Look at New CDK 4/6 Data in Metastatic Breast Cancer
ASCO 2017 featured a number of important studies looking at the role of CDK 4/6 inhibitors in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 5, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Is APHINITY the End of the Line for Trastuzumab Add-ons? Is APHINITY the End of the Line for Trastuzumab Add-ons?
The addition of pertuzumab to standard trastuzumab therapy in patients with early HER2-positive breast cancer led to modest improvements and increased side effects in the APHINITY trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Big Win for PARP Inhibitor in Breast Cancer
(MedPage Today) -- PFS boost for HER2-negative, BRCA-mutated disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 5, 2017 Category: Hematology Source Type: news

APHINITY study shows Roche ’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer
Roche, the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced the Phase III APHINITY study showed adjuvant (after surgery) treatment with the combination of Perjeta ® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) significantly reduced the risk of breast cancer recurrence or death (invasive disease-free survival; iDFS) by 19% in people with HER2-positive early breast cancer (eBC) compared to Herceptin and chemotherapy alon e (HR=0.81; 95% CI 0.66-1.00, p=0.045). (Source: Roche Media News)
Source: Roche Media News - June 5, 2017 Category: Pharmaceuticals Source Type: news

APHINITY study shows Roche ’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer
Roche, the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced the Phase III APHINITY study showed adjuvant (after surgery) treatment with the combination of Perjeta ® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) significantly reduced the risk of breast cancer recurrence or death (invasive disease-free survival; iDFS) by 19% in people with HER2-positive early breast cancer (eBC) compared to Herceptin and chemotherapy alon e (HR=0.81; 95% CI 0.66-1.00, p=0.045). (Source: Roche Investor Update)
Source: Roche Investor Update - June 5, 2017 Category: Pharmaceuticals Source Type: news

Attacking metastatic tumors in the brain
(National Foundation for Cancer Research) Rakesh Jain, Ph.D., Director of the Edwin L. Steele Laboratory for Tumor Biology at the Massachusetts General Hospital and supported by the National Foundation for Cancer Research, has discovered a novel mechanism behind the resistance to HER2- or PI3K-targeted therapies, and a treatment strategy that may overcome treatment resistance. This significant finding was reported in the latest issue of the journal Science Translational Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 5, 2017 Category: Cancer & Oncology Source Type: news

Adding a second HER2 blocker may lower chance of invasive breast cancer for some women
(American Society of Clinical Oncology) A phase III clinical trial of 4,805 women with HER2-positive breast cancer suggests adding a second HER2 targeted medicine, pertuzumab (Perjeta), to standard of care trastuzumab (Herceptin) after surgery may help, although the benefit is modest. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 5, 2017 Category: Cancer & Oncology Source Type: news

Biosimilar May Be As Effective as Trastuzumab for Early Breast Cancer (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH Biosimilar trastuzumab appears to have a similar effect on HER2-positive, early-stage breast cancer as standard trastuzumab (Herceptin), according … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 5, 2017 Category: Primary Care Source Type: news

Olaparib Improves Outcomes in BRCA-Mutated Metastatic Breast Cancer
The PARP inhibitor olaparib increases progression-free survival and improves quality of life in BRCA-mutated HER2-negative metastatic breast cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2017 Category: Cancer & Oncology Authors: Mark Fuerst Tags: Conferences/ASCO Breast Cancer News Source Type: news

Abemaciclib Improves Response, PFS in Endocrine-Resistant Breast Cancer
Abemaciclib plus fulvestrant was linked with improved response and PFS in patients with endocrine-resistant, HR-positive, HER2-negative metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Breast Cancer News Source Type: news

Palbociclib Might Reverse Acquired Breast Cancer Endocrine Resistance
Palbociclib alone and in combination with endocrine therapy offers clinical benefit among women with HR-positive, HER2-negative metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Breast Cancer News Source Type: news

Olaparib: New Standard for BRCA-Mutated Breast Cancer? Olaparib: New Standard for BRCA-Mutated Breast Cancer?
The PARP inhibitor olaparib (Lynparza) showed significant benefit in patients with HER2-negative metastatic breast cancer with a BRCA mutation.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Novartis presents updated data that reinforce the efficacy and safety of Kisqali ® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
Novartis announced today updated findings from the Phase III MONALEESA-2 study that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer. (Source: World Pharma News)
Source: World Pharma News - June 2, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Final TH3RESA, EMILIA Results Confirm Role of Trastuzumab Emtansine in HER2+ Breast Cancer
Final results from two large phase III trials confirm that the drug-antibody conjugate trastuzumab emtansine improves overall survival over other treatment options in patients with previously treated HER2-positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 25, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news